How I treat Adult T-cell leukemia/lymphoma
A partir de données de 4 études de cas, cette étude présente les avancées récentes pour traiter des patients adultes atteints d'un lymphome/leucémie à cellules T
Adult T-cell Leukaemia/lymphoma (ATL) is a highly aggressive T-cell malignancy that arises in a proportion of individuals who are long-term carriers of human T-lymphotropic virus type 1 (HTLV-1). The median survival of aggressive subtypes is 8-10 months, and with chemotherapy-based approaches, the overall survival has remained largely unchanged in ~35 years since first described. Through the use of four representative case studies, we highlight advances in the biological understanding of ATL, the use of novel therapies such as mogamulizumab, and how they are best applied to different subtypes of ATL. We discuss the implementation of molecular methods that may guide diagnosis or treatment, although accept these are not universally available. In particular, we acknowledge discrepancies in treatment between different countries, reflecting current drug licensing and the difficulties in making treatment decisions in a rare disease, with limited high quality clinical trial data.
Blood 2020